Introduction {#s1}
============

Gastroesophageal reflux disease (GERD) is a common chronic disorder characterized by an imbalance of the barrier between the stomach and the esophagus, resulting in the regurgitation of gastric contents into the esophagus amd even the hypopharynx ([@B7]). Based on the Montreal definition published in 2006, it is subclassified into non-erosive reflux disease (NERD), reflux esophagitis (RE), and Barrett esophagus (BE) ([@B43]). Moreover, epidemiological investigation showed that this disease affected approximately 20%\~30% of the population around the world and 7.8%\~8.8% in East Asia ([@B11]). Without timely treatment, patients with the condition will suffer from numerous complications including esophageal stricture, ulceration, and even BE ([@B13]; [@B39]), thereby leading to huge psychological burden and poor work productivity ([@B44]; [@B30]).

Currently, the first-line medical drug for GERD is proton pump inhibitors (PPIs). They are estimated to provide about a 56%\~76% rate of relief of related symptoms and an 80%\~85% recovery rate for esophageal lesions ([@B19]) as well as reducing the incidence of complications ([@B36]). However, approximately 30% GERD sufferers, who had unsatisfactory responses to PPIs still remained symptomatic and had high risk of complications, including BE ([@B12]). Therefore, in order to seek other effective therapies and improve their quality of life, many patients put their attention on alternative medicine ([@B32]).

The use of traditional Chinese medicine (TCM) has a long history and was first documented by the *Sheng Nong Classic of Materia Medica*. Currently, traditional Herbal Medicines (THM) are widely used in cardio-cerebrovascular, endocrine, gastrointestinal, neuropsychiatric, and respiratory disorders ([@B6]; [@B18]; [@B20]; [@B33]; [@B14]; [@B26]; [@B55]). Several studies have evaluated the efficacy and safety of THM in treating GERD ([@B24]; [@B5]; [@B40]). However, these findings were obtained from pairwise comparisons between a prescription and conventional Western medicine(s). No comparison within different THM was conducted in the treatment of GERD. Consequently, to obtain up-to-date information regarding the effectiveness of different prescriptions in treating this disorder, a Bayesian network analysis that integrated direct with indirect evidence for multiple intervention comparisons was performed in this study.

Methods {#s2}
=======

This study was performed based on the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISRMA) ([@B23]) statement and the Cochrane Handbook for the Systematic Review of interventions (details *via* <http://training/cochrane.org/handbook>).

Data Sources and Search Strategy {#s2_1}
--------------------------------

We systematically searched the following databases from their inception to November 30, 2019: PubMed, MEDLINE, EMBASE, Cochrane Library, Scopus, Clarivate, and the Chinese databases of CNKI, WanFang, and VIP for relevant literature. The pre-established search terms consisted of three parts: strategies for GRED, THM treatment, and a specific filter for randomized controlled trials. Both Medical Subject Headings (MeSH) terms and text words were used for keywords. The detailed search strategies for each database are shown in [**Supplementary Table S1**](#ST1){ref-type="supplementary-material"}. No limitation was placed on language of article. Any omission of publications was remedied by manual retrieval. To obtain eligible trials, the reference lists of the included studies were checked for verification and further assessment.

Study Selection {#s2_2}
---------------

Following the PICOS (participants, interventions, comparisons, outcomes, and study design) criteria, two investigators (Yun-kai Dai, Yun-bo Wu) preliminarily screened the relevant titles and abstracts. Randomized, parallel-group clinical trials of THM for GERD were initially included. The full texts of these studies were then scanned for further evaluation. Briefly, participants over the age of 18 should meet the diagnosis criteria of GERD ([@B7]). Any prescription of THM interventions and certain positive controls (PPIs, or gastrointestinal motility drugs (GMD), or combinations) were selected. Meanwhile, the sample size of each trial should not be less than 30/arm, and the duration of treatment should be at least 4 weeks. In order to obtain superior quality literature, works with a Jadad score above 1 was screened.

However, some participants or publications were excluded: pregnant women, patients with comorbidities such as severe cardio-cerebro-vascular diseases and cancers, published meeting abstracts, non-research articles and cross-over studies, and THM as positive control.

Data Abstraction and Quality Evaluation {#s2_3}
---------------------------------------

Using a prepiloted data extraction sheet, two researchers (Yun-kai Dai, Yun-bo Wu) independently conducted data abstraction and quality assessment. Relevant characteristics of participants (gender, age, and sample size), details of interventions and comparisons (regimen for treatment and duration), course of disease, primary outcomes (overall clinical efficacy and efficacy under gastroscope) and secondary outcomes (improvements of acid regurgitation and heartburn, reflux diagnostic questionnaire (RDQ) scores), side effects, and study design were extracted, as was the classification of GERD. Moreover, relevant missing information could be acquired if necessary through telephoning the corresponding authors.

On the basis of the Cochrane Collaboration Recommendations assessment tool ([@B38]), the quality of the included trials was independently evaluated by two reviewers (Yun-kai Dai, Yun-bo Wu). Overall evaluation of methodological quality had seven aspects: (i) random sequence generation; (ii) allocation concealment; (iii) blinding of participants and personnel; (iv) blinding (or masking) of outcomes assessment; (v) incomplete outcome data; (vi) selective reporting; (vii) other bias. Disagreements were resolved by further discussion or negotiation. For the methodological quality attribute of each study, the value "high quality" (or low risk), "uncertain quality" (or unclear risk), or "low quality" (or high risk) was assigned to calculate the overall score, which ranged from 0 to 6 points (from worst to best methodological quality). In view of this, the distributions of the methodological qualities on different comparisons across the evidence network were assessed. In addition, the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) profiler version 3.6 was used to analyze the overall evidence quality of this network analysis.

Statistical Analysis {#s2_4}
--------------------

Evidence of direct and indirect multiple-intervention comparisons is obtained by network meta-analysis, and performing this analysis with the Bayesian framework can improve the accuracy of the results. WinBUGS version 1.4.3 (MRC Biostatistics Unit, Cambridge, UK), based on the Bayesian framework and the Markov chain Monte Carlo (MCMC) method, was used to assess and process research data a priori. We used non-informative uniform and normal prior distributions ([@B1]; [@B41]) and three Markov chains to fit the model. Meanwhile, 50,000 simulation iterations and 10 thining intervals per chain were set to gain the posterior distributions of model parameters. The first 20,000 iterations were used for burn-in so as to eliminate the effects of initial value scaling, while the last 30,000 were applied to sampling. A relationship between direct and indirect multiple-intervention comparisons was drawn as a network figure using Stata version 13.0 software. The Brooks-Gelman-Rubin statistic was calculated to evaluate model convergence. The closer the potential scale reduction factor (PSRF) value was to 1, the better the convergence. Of course, a PSRF value of less than 1.2 was still acceptable. The node-splitting analysis was evaluated to test the consistency ([@B8]). If the *p*-value was greater than 0.05, a consistency model would be used. Otherwise, an inconsistency model was used. Accordingly, sensitivity analysis was used to test the source of heterogeneity. To summarize the probabilities for all interventions, the surface under the cumulative ranking curve (SUCRA) was used as a summary statistic for the cumulative ranking ([@B35]). Based on the definition, the larger SUCRA scores are, the more effective the interventions are. In this study, the effect sizes of all outcomes were analyzed by a fixed or random effect model depending on indexes of statistical heterogeneity including the *p*-value and inconsistency index statistic (*I^2^*) ([@B16]). Dichotomous outcomes were calculated using the odds ratio (OR) and 95% credible intervals (CrIs). Continuous variable data were evaluated using the mean difference (MD) and with their corresponding 95% CrIs.

Results {#s3}
=======

Study Identification and Selection {#s3_1}
----------------------------------

In total, 2679 articles were retrieved from the nine databases according to the corresponding search strategies. After removing duplicates and irrelevant publications, 17 randomized controlled trials (RCTs) including 1441 participants were selected for further quantitative analyses. A flow diagram of the specific retrieval process is shown in [**Figure 1**](#f1){ref-type="fig"}. The baseline characteristics of the included trials are displayed in [**Table 1**](#T1){ref-type="table"}. The classification of herbal medicines and usage frequency of the included herbs can be found in [**Table 2**](#T2){ref-type="table"} and [**Figure 2**](#f2){ref-type="fig"}. Accordingly, we could draw a rough conclusion that herbs with the function of regulating the liver and harmonizing the stomach (TCM jargon: Ligan Hewei) and invigorating spleen (TCM jargon: Jianpi) had higher frequencies among the included herbs.

![Flow diagram.](fphar-11-00884-g001){#f1}

###### 

Characteristics of the studies included in the network analysis.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study ID   Country/Affiliation of the first author                                                                                 Classification of GERD   Sample Size   Age (years)   Course of disease(months)   Duration(weeks)     Intervention   Outcomes               Follow-up   Side effects                              
  ---------- ----------------------------------------------------------------------------------------------------------------------- ------------------------ ------------- ------------- --------------------------- ------------------- -------------- ---------------------- ----------- ------------------------------ ---------- -------------------------------------------------------------
  [@B21]     China/Department of Spleen and Stomach Diseases, Beijing Hospital of TCM Affiliated to the Capital Medical University   N/A                      38 (15/23)    36\           E: 47. 42 ± 11.91\          E: 52.08 ± 51.60\   6              Jianpi therapy         PPIs        ![](fphar-11-00884-g008.jpg)   N/A        N/A
                                                                                                                                                                            (22/14)       C: 49. 89 ± 11.82           C: 40.32 ± 34.44                                                                                                

  [@B40]     China (Taiwan)/Graduate Institute of Integrated Medicine, College of Chinese Medicine                                   N/A                      40\           37\           E: 46.03 ± 13.88\           N/A                 4              Jianpi therapy         PPIs        ![](fphar-11-00884-g009.jpg)   N/A        E: 1 for epigastric pain\
                                                                                                                                                              (14/26)       (20/17)       C: 46.95 ± 13.42                                                                                                                            1 for bitter taste\
                                                                                                                                                                                                                                                                                                                                      1 for fever sensation\
                                                                                                                                                                                                                                                                                                                                      C:1 for abdominal pain\
                                                                                                                                                                                                                                                                                                                                      2 for epigastric pain\
                                                                                                                                                                                                                                                                                                                                      1 for worsened acid reflux

  [@B25]     China/First People's Hospital Affiliated to Shanghai Jiaotong University                                                RE                       60\           60\           E: 47.55 ± 12.44\           E: 85.08 ± 48.12\   8              Ligan Hewei therapy    PPIs        ![](fphar-11-00884-g010.jpg)   N/A        E: abdominal distension, nausea, insomnia, cold, rhinitis.\
                                                                                                                                                              (24/36)       (32/28)       C: 46.03 ± 11.36            C: 83.76 ± 47.16                                                                                                C: nausea, diarrhea, tinnitus, swelling, aching of gums

  [@B53]     China/Shanghai Fenglin Community Health Service Center of Xuhui District                                                N/A                      43\           42\           E: 46.63 ± 13.80\           E: 10.95 ± 2.69\    8              Jianpi therapy         PPIs        ![](fphar-11-00884-g011.jpg)   N/A        N/A
                                                                                                                                                              (19/24)       (21/21)       C: 49.19 ± 11.75            C: 10.62 ± 3.59                                                                                                 

  [@B22]     China/Chengdu University of TCM                                                                                         N/A                      30\           30\           E: 2.13 ± 14.08\            E: 37.72 ± 7.82\    8              Ligan Hewei therapy    PPIs\       ![](fphar-11-00884-g012.jpg)   N/A        N/A
                                                                                                                                                              (17/13)       (18/12)       C: 52.47 ± 13.71            C: 38.88 ± 7.12                                           +GMD                                                  

  [@B46]     China/Chengdu University of TCM                                                                                         RE                       30\           30\           E: 52.58 ± 6.22\            E: 19.77 ± 8.11\    8              Jianpi therapy         PPIs        ![](fphar-11-00884-g013.jpg)   N/A        N/A
                                                                                                                                                              (14/16)       (15/15)       C: 53.52 ± 7.19             C: 20.07 ± 8.26                                                                                                 

  [@B17]     China/Department of Spleen and Stomach Diseases, Yancheng Hospital of TCM                                               NERD                     43\           43\           E: 40.50 ± 9.40\            E: 76.80 ± 64.80\   4              Ligan Hewei therapy    PPIs        ![](fphar-11-00884-g014.jpg)   N/A        E: diarrhea
                                                                                                                                                              (25/18)       (23/20)       C: 41.70 ± 11.20            C: 80.40 ± 69.60                                                                                                

  [@B54]     China/The Second Clinical Medical College, Henan University of TCM                                                      N/A                      40\           40\           E: 53.30 ± 5.10\            N/A                 8              Ligan Hewei therapy    PPIs        ![](fphar-11-00884-g015.jpg)   N/A        N/A
                                                                                                                                                              (25/15)       (19/21)       C: 55.60 ± 5.60                                                                                                                             

  [@B48]     China/Xiangcheng District TCM Hospital of Suzhou City                                                                   N/A                      65\           62\           E:\                         E: 20.10 ± 16.80\   8              Ligan Hewei therapy    PPIs\       ![](fphar-11-00884-g016.jpg)   N/A        N/A
                                                                                                                                                              (30/35)       (28/34)       45.80 ± 13.10\              C: 18.30 ± 16.20                                          +GMD                                                  
                                                                                                                                                                                          C: 46.30 ± 12.70                                                                                                                            

  [@B52]     China/Shandong University of TCM                                                                                        N/A                      30\           30\           E: 48.90 ± 7.50\            E: 45.30 ± 3.80\    12             Ligan Hewei therapy    PPIS\       ![](fphar-11-00884-g017.jpg)   N/A        E: N/A\
                                                                                                                                                              (10/20)       (11/19)       C: 49.20 ± 8.10             C: 46.20 ± 5.10                                           +GMD                                                  C: 2 for nausea

  [@B34]     Japan/Department of Internal Medicine and Gastroenterology, Saga Medical School                                         NERD                     52\           43\           E: 72.10\                   N/A                 8              Jianpi therapy         PPIs        ![](fphar-11-00884-g018.jpg)   N/A        N/A
                                                                                                                                                              (17/35)       (8/35)        C: 73.40                                                                                                                                    

  [@B45]     China/Shanxi University of Chinese Medicine                                                                             RE                       33\           34\           E: 45.12 ± 6.32\            E: 42.72 ± 27.60\   8              Ligan Hewei therapy\   PPIs        ![](fphar-11-00884-g019.jpg)   N/A        E:3 for slight nausea.\
                                                                                                                                                              (20/13)       (22/12)       C: 46.78 ± 9.77             C: 49.20 ± 19.80                   +PPIs                                                                        C: 6 for nausea, poor appetite, and diarrhea.

  [@B4]      China/Yueyang Hospital of Integrative Chinese and Western Medicine Affiliated to Shanghai University of TCM             NERD                     30\           30\           E: 50.47 ± 11.62\           N/A                 8              Ligan Hewei therapy    PPIs        ![](fphar-11-00884-g020.jpg)   N/A        N/A
                                                                                                                                                              (12/18)       (7/23)        C: 46.63 ± 12.40                                                                                                                            

  [@B42]     Japan/Department of Gastroenterology, Osaka City University Graduate School of Medicine                                 N/A                      50\           51\           E: 63.60\                   N/A                 4              Jianpi therapy         PPIs        ![](fphar-11-00884-g021.jpg)   N/A        N/A
                                                                                                                                                              (20/30)       (17/34)       C: 64.50                                                                                                                                    

  [@B15]     China/Shanxi Medical University                                                                                         N/A                      40\           40\           E: 59.40 ± 7.80\            N/A                 4              Ligan Hewei therapy    GMD         ![](fphar-11-00884-g022.jpg)   2 months   N/A
                                                                                                                                                              (24/16)       (23/17)       C: 58.50 ± 11.40                                                                                                                            

  [@B56]     China/Nanjing University of Chinese Medicine                                                                            N/A                      55\           54\           E: 49.20 ± 13.10\           N/A                 8              Jianpi therapy\        PPIs        ![](fphar-11-00884-g023.jpg)   1 month    N/A
                                                                                                                                                              (31/24)       (30/24)       C: 46.80 ± 12.40                                               +PPIs                                                                        

  [@B57]     China/Shanghai Hospital of TCM Attached to Shanghai University of TCM                                                   N/A                      50\           50\           E: 51.48\                   E: 34.80\           8              Ligan Hewei therapy    PPIs        ![](fphar-11-00884-g024.jpg)   N/A        N/A
                                                                                                                                                              (16/34)       (14/36)       C: 48.98                    C: 44.04                                                                                                        
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Annotations: E, experimental group; C, control group; N/A, not applicable; TCM, traditional Chinese medicine; GERD, gastroesophageal reflux disease; NERD, non-erosive reflux disease; RE, reflux esophagitis; M, male; F, female; PPIs, proton pump inhibitors; GMD, gastrointestinal motility drugs; ![](fphar-11-00884-i001.jpg), overall clinical efficacy; ![](fphar-11-00884-i002.jpg), TCM symptom scores (belching, acid regurgitation, heartburn, sternalgia); ![](fphar-11-00884-i003.jpg), efficacy under gastroscope; ![](fphar-11-00884-i004.jpg), recurrence rate; ![](fphar-11-00884-i005.jpg), adverse effect rate; ![](fphar-11-00884-i006.jpg), FSSG questionnaire frequency scale for the symptoms of GERD; ![](fphar-11-00884-i007.jpg), Reflux Disease Questionnaire (RDQ); ![](fphar-11-00884-i008.jpg), GERD Questionnaire scores (GerdQ); ![](fphar-11-00884-i009.jpg), The short-form health survey questionnaire (SF 36); ![](fphar-11-00884-i010.jpg), 24-hour esophageal pH monitoring; ![](fphar-11-00884-i012.jpg), GERD Health-Related Quality of Life Questionnaire (GERD-HRQL); ![](fphar-11-00884-i013.jpg), Pittsburgh Sleep Quality Index (PSQI); ![](fphar-11-00884-i014.jpg), Hospital Anxiety and Depression Scale (HADS); ![](fphar-11-00884-i015.jpg), clinical symptoms scores; ![](fphar-11-00884-i016.jpg), Serum Ghrelin, LPO level; ![](fphar-11-00884-i017.jpg), total clinical symptoms score; ![](fphar-11-00884-i018.jpg), scores of gastroscopy evaluation; ![](fphar-11-00884-i019.jpg), pressure of upper esophageal sphincter (UES) and lower esophageal sphincter (LES); ![](fphar-11-00884-i020.jpg), scores of the pattern of depressed liver and stomach qi transforming into fire; ![](fphar-11-00884-i021.jpg), scores of anxiety and depression; ![](fphar-11-00884-i022.jpg), Gastrointestinal Symptom Rating Scale (GSRS); ![](fphar-11-00884-i023.jpg), total scores of symptoms and physical signs; ![](fphar-11-00884-i024.jpg), efficacy of main symptoms (belching, regurgitation, heartburn, sternalgia).

###### 

The ingredients of each formula in the included trials.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                                                     Ingredients of each formula                                                                                                                              
  ---------------------------------------------------------- ---------------------------------------------------- ------------------------------------------------- ------------------------------------------------- --------------------------------------------
  [@B21]                                                     *Codonopsis pilosula (Franch.) Nannf.*\              *Allium macrostemon Bge.*\                        *Atractylodes lancea (Thunb.) DC.* (Cang Zhu)     *Trichosanthes kirilowii Maxim.*\
                                                             (Dang Shen)                                          (Xie Bai)                                                                                           (Gua Lou Pi)

  *Coptis chinensis Franch.*\                                *Evodia cuspidata K.Schum.*\                         *Aucklandia lappa DC.*\                           *Eugenia abbreviata Urb.*\                        
  (Huang Lian)                                               (Wu Zhu Yu)                                          (Mu Xiang)                                        (Ding Xiang)                                      

  *Citrus reticulata Blanco*\                                *Aesculus chinensis Bge*\                            *Pinellia ternata (Thunb) Breit.*\                *Citrus mitis Blanco*\                            
  (Qing Pi)                                                  (Suo Luo Zi)                                         (Ban Xia)                                         (Chen Pi)                                         

  *Bambusa tuldoides Munro*\                                                                                                                                                                                          
  (Zhu Ru)                                                                                                                                                                                                            

  [@B40]                                                     *Evodia cuspidata K.Schum.*\                         *Panax ginseng C.A. Mey*\                         *Ziziphus jujuba Mill*\                           *Zingiber Officinale Roscoe* (Sheng Jiang)
                                                             (Wu Zhu Yu)                                          (Ren Shen)                                        (Da Zao)                                          

  [@B25]                                                     *Dendrobium loddigesii Rolfe.*\                      *Anemarrhena asphodeloides Bge.*\                 *Coptis chinensis Franch.*\                       *Sophora flavescens Ait.*\
                                                             (Shi Hu)                                             (Zhi Mu)                                          (Huang Lian)                                      (Ku Shen)

  *Poria cocos (Schw.) Wolf*\                                *Atractylodes macrocephala Koidz.*\                  *Bletilla striata (Thunb.) Reichb. F.* (Bai Ji)   *Astragalus mongholicus Bunge*\                   
  (Fu Lin)                                                   (Bai Zhu)                                                                                              (Huang Qi)                                        

  *Portulaca oleracea L.*\                                   *Citrus aurantium L.*\                               *Clematis chinensis Osbeck*\                      *Iris domestica (L.) Goldblatt & Mabb.*\          
  (Ma Chi Xian)                                              (Zhi Qiao)                                           (Wei Ling Xian)                                   (She Gan)                                         

  *Forsythia suspensa (Thunb.) Vahl*\                        *Sanguisorba officinalis L.*\                                                                                                                            
  (Lian Qiao)                                                (Di Yu)                                                                                                                                                  

  [@B53]                                                     *Atractylodes macrocephala Koidz.*\                  *Eriobotrya japonica (Thunb.) Liindl.*\           *Platycodon grandiflorum (Jacq.) A.DC*\           
                                                             (Bai Zhu)                                            (Pi Pa Ye)                                        (Jie Geng)                                        

  [@B22]                                                     *Bupleurum chinensis DC.*\                           *Citrus aurantium L.*\                            *Paeonia lactiflora Pall.*\                       *Radix Glycyrrhizae preparata*\
                                                             (Chai Hu)                                            (Zhi Qiao)                                        (Chi Shao)                                        (Gan Cao)

  *Astragalus mongholicus Bunge*\                            *Cyperus rotundus L.*\                               *Massa Medicata Fermentata*\                      *Pinellia ternata (Thunb) Breit.*\                
  (Huang Qi)                                                 (Xiang Fu)                                           (Shen Qu)                                         (Ban Xia)                                         

  *Corydalis yanhusuo W.T. Wang*\                            *Allium macrostemon Bge.*\                           *Trichosanthes kirilowii Maxim.*\                 *Inula japonica Thunb.*\                          
  (Yan Hu Suo)                                               (Xie Bai)                                            (Gua Lou Pi)                                      (Xuan Fu Hua)                                     

  *Raphanus raphanistrum subsp. sativus (L.) Domin*\         *Scutellaria baicalensis Georg*\                                                                                                                         
  (Lai Fu Zi)                                                (Huang Qin)                                                                                                                                              

  [@B46]                                                     *Astragalus mongholicus Bunge*\                      *Panax ginseng C.A. Mey*\                         *Cinnamomum cassia Presl*\                        *Paeonia lactiflora Pall.*\
                                                             (Huang Qi)                                           (Ren Shen)                                        (Rou Gui)                                         (Bai Shao)

  *Zingiberis rhizoma*\                                      *Ziziphus jujuba Mill*\                              *Radix Glycyrrhizae preparata*\                   *Aconitum carmichaeli Debx*\                      
  (Gan Jiang)                                                (Da Zao)                                             (Gan Cao)                                         (Fu Zi)                                           

  *Pinellia ternata (Thunb) Breit.*\                                                                                                                                                                                  
  (Ban Xia)                                                                                                                                                                                                           

  [@B17]                                                     *Coptis chinensis Franch.*\                          *Corydalis yanhusuo W.T. Wang*\                   *Citrus mitis Blanco*\                            *Cleistocactus sepium*\
                                                             (Huang Lian)                                         (Yan Hu Suo)                                      (Chen Pi)                                         (Wu Zei Gu)

  *Pinellia ternata (Thunb) Breit.*\                         *Fritillaria cirrhosa D. Dom*\                       *Magnolia officinals Rehd.et Wils.* (Hou Po)      *Inula japonica Thunb.*\                          
  (Ban Xia)                                                  (Chuan Bei Mu)                                                                                         (Xuan Fu Hua)                                     

  *Oldenlandia diffusa (Willd.) Roxb.*\                      *Lonicera japonica Thunb.*\                          *Ophiopogon japonicus (Thunb.) Ker-Gawl.*\        *Radix Glycyrrhizae preparata*\                   
  (Bai Hua She She Cao)                                      (Jin Yin Hua)                                        (Mai Dong)                                        (Gan Cao)                                         

  [@B54]                                                     *Citrus mitis Blanco*\                               *Pinellia ternata (Thunb) Breit.*\                *Bletilla striata (Thunb.) Reichb. F.* (Bai Ji)   *Sepiella maindroni de Rochebrune*\
                                                             (Chen Pi)                                            (Ban Xia)                                                                                           (Hai Piao Xiao)

  *Fritillaria cirrhosa D. Dom*\                             *Arca subcrenata Lischke*\                           *Ostreagigas Thunberg*\                           *Coptis chinensis Franch.*\                       
  (Chuan Bei Mu)                                             (Duan Wa Leng)                                       (Duan Mu Li)                                      (Huang Lian)                                      

  *Evodia cuspidata K.Schum.*\                               *Nardostachys jatamansi DC.*\                                                                                                                            
  (Wu Zhu Yu)                                                (Gan Song)                                                                                                                                               

  [@B48]                                                     *Coptis chinensis Franch.*\                          *Evodia cuspidata K.Schum.*\                      *Pinellia ternata (Thunb) Breit.*\                *Magnolia officinals Rehd.et Wils.*\
                                                             (Huang Lian)                                         (Wu Zhu Yu)                                       (Ban Xia)                                         (Hou Po)

  *Poria cocos (Schw.) Wolf*\                                *Zingiber Officinale Roscoe*\                        *Folium Perillae*\                                *Inula japonica Thunb.*\                          
  (Fu Lin)                                                   (Sheng Jiang)                                        (Zi Su Ye)                                        (Xuan Fu Hua)                                     

  *Gardenia jasminoides Ellis*\                              *Melia azedarach L.*\                                *Cyperus rotundus L.*\                            *Gentiana manshurica Kitag.* (Long Dan Cao)       
  (Zhi Zi)                                                   (Chuan Lian Zi)                                      (Xiang Fu)                                                                                          

  *Bupleurum chinensis DC.*\                                 *Radix Glycyrrhizae preparata*\                                                                                                                          
  (Chai Hu)                                                  (Gan Cao)                                                                                                                                                

  [@B52]                                                     *Bupleurum chinensis DC.*\                           *Coptis chinensis Franch.*\                       *Evodia cuspidata K.Schum.*\                      *Paeonia lactiflora Pall.*\
                                                             (Chai Hu)                                            (Huang Lian)                                      (Wu Zhu Yu)                                       (Bai Shao)

  *Citrus aurantium L.*\                                     *Atractylodes macrocephala Koidz.*\                  *Pinellia ternata (Thunb) Breit.*\                *Poria cocos (Schw.)Wolf*\                        
  (Zhi Qiao)                                                 (Bai Zhu)                                            (Ban Xia)                                         (Fu Lin)                                          

  *Aucklandia lappa DC.*\                                    *Amomum villosum Lour.*\                             *Folium Perillae*\                                *Eriobotrya japonica (Thunb.) Liindl.*\           
  (Mu Xiang)                                                 (Sha Ren)                                            (Zi Su Ye)                                        (Pi Pa Ye)                                        

  *Arca subcrenata Lischke*\                                 *Radix Glycyrrhizae preparata*\                                                                                                                          
  (Duan Wa Leng)                                             (Gan Cao)                                                                                                                                                

  [@B34]                                                     *Atractylodes macrocephala Koidz.*\                  *Panax ginseng C.A. Mey*\                         *Pinellia ternata (Thunb) Breit.*\                *Poria cocos (Schw.) Wolf*\
                                                             (Bai Zhu)                                            (Ren Shen)                                        (Ban Xia)                                         (Fu Lin)

  *Ziziphus jujuba Mill*\                                    *Citrus mitis Blanco*\                               *Radix Glycyrrhizae preparata*\                   *Zingiberis rhizoma*\                             
  (Da Zao)                                                   (Chen Pi)                                            (Gan Cao)                                         (Gan Jiang)                                       

  [@B48]                                                     *Bupleurum chinensis DC.*\                           *Coptis chinensis Franch.*\                       *Paeonia suffruticosa Andr.*\                     *Paeonia lactiflora Pall.*\
                                                             (Chai Hu)                                            (Huang Lian)                                      (Mu Dan Pi)                                       (Bai Shao)

  *Fritillaria cirrhosa D. Dom*\                             *Pinellia ternata (Thunb) Breit.*\                   *Citrus reticulata Blanco*\                       *Evodia cuspidata K.Schum.*\                      
  (Chuan Bei Mu)                                             (Ban Xia)                                            (Qing Pi)                                         (Wu Zhu Yu)                                       

  *Cleistocactus sepium*\                                    *Magnolia officinals Rehd.et Wils.*\                 *Taraxacum mongolicum Hand. -Mazz.*\              *Radix Glycyrrhizae preparata*\                   
  (Wu Zei Gu)                                                (Hou Po)                                             (Pu Gong Ying)                                    (Gan Cao)                                         

  [@B4]                                                      *Inula japonica Thunb.*\                             *Haematite*\                                      *Bupleurum chinensis DC.*\                        *Citrus aurantium L.*\
                                                             (Xuan Fu Hua)                                        (Dai Zhe Shi)                                     (Chai Hu)                                         (Zhi Qiao)

  *Gardenia jasminoides Ellis*\                              *Melia azedarach L.*\                                *Coptis chinensis Franch.*\                       *Evodia cuspidata K.Schum.*\                      
  (Zhi Zi)                                                   (Chuan Lian Zi)                                      (Huang Lian)                                      (Wu Zhu Yu)                                       

  *Zingiber Officinale Roscoe*\                              *Arca subcrenata Lischke*\                           *Radix Glycyrrhizae preparata*\                                                                     
  (Sheng Jiang)                                              (Duan Wa Leng)                                       (Gan Cao)                                                                                           

  [@B42]                                                     *Atractylodes macrocephala Koidz.*\                  *Panax ginseng C.A. Mey*\                         *Pinellia ternata (Thunb) Breit.*\                *Poria cocos (Schw.) Wolf*\
                                                             (Bai Zhu)                                            (Ren Shen)                                        (Ban Xia)                                         (Fu Lin)

  *Ziziphus jujuba Mill*\                                    *Citrus mitis Blanco*\                               *Radix Glycyrrhizae preparata*\                   *Zingiberis rhizoma*\                             
  (Da Zao)                                                   (Chen Pi)                                            (Gan Cao)                                         (Gan Jiang)                                       

  [@B15]                                                     *Bupleurum chinensis DC.*\                           *Paeonia lactiflora Pall.*\                       *Citrus aurantium L.*\                            *Citrus mitis Blanco*\
                                                             (Chai Hu)                                            (Bai Shao)                                        (Zhi Qiao)                                        (Chen Pi)

  *Conioselinum chinense (L.) Britton, Sterns & Poggenb.*\   *Gardenia jasminoides Ellis*\                        *Coptis chinensis Franch.*\                       *Pinellia ternata (Thunb) Breit.*\                
  (Chuan Xiong)                                              (Zhi Zi)                                             (Huang Lian)                                      (Ban Xia)                                         

  *Evodia cuspidata K.Schum.*\                               *Raphanus raphanistrum subsp. sativus (L.) Domin*\   *Hyriopsis cumingii (Lea)*\                       *Radix Glycyrrhizae preparata*\                   
  (Wu Zhu Yu)                                                (Lai Fu Zi)                                          (Zhen Zhu Mu)                                     (Gan Cao)                                         

  [@B56]                                                     *Coptis chinensis Franch.*\                          *Evodia cuspidata K.Schum.*\                      *Codonopsis pilosula (Franch.) Nannf.*\           *Inula japonica Thunb.*\
                                                             (Huang Lian)                                         (Wu Zhu Yu)                                       (Dang Shen)                                       (Xuan Fu Hua)

  *Haematite*\                                               *Scutellaria baicalensis Georg*\                     *Cleistocactus sepium*\                           *Fritillaria cirrhosa D. Dom* (Chuan Bei Mu)      
  (Dai Zhe Shi)                                              (Huang Qin)                                          (Wu Zei Gu)                                                                                         

  *Agrimonia pilosa Ledeb.*\                                 *Bletilla striata (Thunb.) Reichb. F.*\              *Citrus aurantium L.*\                            *Magnolia officinals Rehd.et Wils.*\              
  (Xian He Cao)                                              (Bai Ji)                                             (Zhi Qiao)                                        (Hou Po)                                          

  [@B57]                                                     *Eriobotrya japonica (Thunb.) Liindl.*\              *Platycodon grandiflorum (Jacq.) A.DC*\           *Atractylodes macrocephala Koidz.* (Bai Zhu)      
                                                             (Pi Pa Ye)                                           (Jie Geng)                                                                                          
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Annotations: Italics are Latin terms for herbs. Non-italics are Chinese pinyin for herbs.

![Usage frequency of the included herbs.](fphar-11-00884-g002){#f2}

Risk of Bias Evaluation {#s3_2}
-----------------------

On the basis of the Cochrane Collaboration Recommendations evaluation tools ([@B37]), the quality of the included RCTs was assessed. Of all the studies, 82.35% (14/17) gave a specific description of the random-allocation process, such as the use of a random number table or a computer-generated randomization list. The others only used the word "randomization" without any explanation. Because of insufficient information about allocation concealment, all included trials were judged as of "unclear risk." In performance bias, only four studies (23.53%) described double or single blinding. As for detection bias, 13 trials (76.47%) either could not be blinded or it was unclear whether they had been. In addition, eight RCTs (47.06%) were at low risk of attrition bias because they provided detailed explanations or statistical estimations of dropout rates. However, two trials (11.76%) failed to provide adequate information for the judgment of missing data risk. Moreover, there was insufficient information on other risks for all 17 studies. In sum, among all trials, 4 were viewed as low risk, 2 as unclear risk, and 11 as high risk. A detailed quality evaluation is shown in [**Figures 3A, B**](#f3){ref-type="fig"}.

![Risk of bias. **(A)** Summary. **(B)** Graph.](fphar-11-00884-g003){#f3}

Network Evidence {#s3_3}
----------------

This study included seven regimens as follows: Ligan Hewei therapy, Ligan Hewei therapy+PPIs, Jianpi therapy, Jianpi therapy+PPIs, PPIs, PPIs+GMD, and GMD. The results of the network analysis suggested that the number of GERD patients treated with PPIs was the largest, followed by Ligan Hewei therapy and then Jianpi therapy, while the number of GERD patients treated with Ligan Hewei therapy+PPIs was the smallest ([**Figure 4**](#f4){ref-type="fig"}).

![Network evidence diagrams of four endpoints. **(A)** Overall clinical efficacy. **(B)** Improvement of acid regurgitation. **(C)** Efficacy under gastroscope. **(D)** Improvement of heartburn.](fphar-11-00884-g004){#f4}

Major Results of Network Analysis {#s3_4}
---------------------------------

In this study, there were 14 publications reporting overall clinical efficacy, 7 reporting the improvement of gastroesophageal mucosal lesions when viewed under a gastroscope (namely efficacy under gastroscope), 5 reporting improvement of acid regurgitation, and 4 reporting heartburn improvement. As shown in [**Table S2**](#ST2){ref-type="supplementary-material"}, the results of node-splitting between the direct and indirect effects showed no inconsistency for the four outcomes (P\>0.05). Meanwhile, the PSRF value with 1 or 1.01 indicated good convergence and a stable result. Therefore, a model of consistency was built. As displayed in [**Table 3**](#T3){ref-type="table"}, Ligan Hewei therapy was significantly better overall clinical efficacy than PPIs (OR 2.36, 95%CrIs 1.16 to 5.24) and GMD+PPIs (OR 2.99, 95%CrIs 1.09 to 8.60). For the improvement of acid regurgitation, Ligan Hewei therapy+PPIs (MD -1.51, 95%CrIs -3.45 to 0.48), Ligan Hewei therapy (MD -1.07, 95%CrIs -3.10 to 0.93), and PPIs (MD -0.93, 95%CrIs -2.47 to 0.56) were superior to Jianpi therapy, Ligan Hewei therapy+PPIs (MD -0.58, 95%CrIs -1.84 to 0.74) was better than PPIs, and PPIs+GMD was superior to Jianpi therapy (MD -1.25, 95%CrIs -3.49 to 0.92) and Ligan Hewei therapy (MD -0.18, 95%CrIs -1.13 to 0.71). For heartburn improvement, Ligan Hewei therapy+PPIs (MD -0.76, 95%CrIs -1.73 to 0.24), PPIs+GMD (MD -0.34, 95%CrIs -1.56 to 0.85), and Ligan Hewei therapy (MD -0.19, 95%CrIs -1.18 to 0.78) were better than PPIs, and Ligan Hewei therapy+PPIs (MD -0.56, 95%CrIs -1.91 to 0.83) and PPIs+GMD (MD -0.15, 95%CrIs -0.84 to 0.52) were superior to Ligan Hewei therapy.

###### 

Odds ratios (OR) or mean difference and 95% credible intervals (CrIs) of seven regimes with four endpoints.

  OR/MD (95%CrIs)                                                                                                                                                                        
  ----------------------------------- ------------------------- -------------------------------- ---------------------------- ------------------------- -------------------------------- -----------------------
  **GMD**                             1.09 (0.15, 9.61)         3.43 (0.37, 35.53)               5.37 (0.35, 113.24)          3.29 (0.55, 21.69)        3.27 (0.28, 41.96)               1.38 (0.19, 10.36)
  0.91 (0.10, 6.75)                   **PPIs + GMD**            3.06 (0.60, 15.96)               4.71 (0.46, 72.18)           **2.99 (1.09, 8.60)**     2.95 (0.39, 24.96)               1.26 (0.36, 4.54)
  0.29 (0.03, 2.67)                   0.33 (0.06, 1.68)         **Jianpi therapy**               1.49 (0.17, 19.80)           0.98 (0.25, 3.25)         1.00 (0.14, 5.88)                0.42 (0.14, 1.12)
  0.19 (0.01, 2.87)                   0.21 (0.01, 2.17)         0.67 (0.05, 5.99)                **Jianpi therapy + PPIs**    0.65 (0.05, 5.23)         0.63 (0.04, 7.79)                0.28 (0.02, 1.85)
  0.30 (0.05, 1.82)                   **0.33 (0.12, 0.92)**     1.02 (0.31, 3.98)                1.54 (0.19, 19.54)           **Ligan Hewei therapy**   1.00 (0.18, 5.67)                **0.42 (0.19, 0.86)**
  0.31 (0.02, 3.51)                   0.34 (0.04, 2.59)         1.00 (0.17, 7.36)                1.59 (0.13, 27.40)           1.00 (0.18, 5.62)         **Ligan Hewei therapy + PPIs**   0.43 (0.09, 1.92)
  0.73 (0.10, 5.14)                   0.79 (0.22, 2.79)         2.40 (0.90, 7.38)                3.60 (0.54, 40.86)           **2.36 (1.16, 5.24)**     2.35 (0.52, 11.22)               **PPIs**
                                                                                                                                                                                         
  Efficacy under gastroscope                                                                                                                                                             
  **GMD**                             1.65 (0.10, 26.24)        11.61 (0.25, 568.68)             51.90 (0.92, 3257.59)        7.11 (0.74, 68.82)        26.28 (0.58, 1280.91)            7.98 (0.31, 175.41)
  0.61 (0.04, 9.72)                   **PPIs + GMD**            6.89 (0.21, 254.10)              31.25 (0.78, 1584.93)        4.25 (0.88, 22.93)        16.30 (0.54, 600.63)             4.83 (0.33, 75.59)
  0.09 (0.00, 3.99)                   0.15 (0.00, 4.80)         **Jianpi therapy**               4.24 (0.18, 128.60)          0.61 (0.03, 13.90)        2.29 (0.11, 48.17)               0.69 (0.07, 5.85)
  0.02 (0.00, 1.09)                   0.03 (0.00, 1.27)         0.24 (0.01, 5.64)                **Jianpi therapy + PPIs**    0.14 (0.00, 3.71)         0.55 (0.02, 14.63)               0.17 (0.01, 1.87)
  0.14 (0.01, 1.35)                   0.24 (0.04, 1.14)         1.64 (0.07, 37.39)               7.19 (0.27, 247.10)          **Ligan Hewei therapy**   3.73 (0.18, 87.69)               1.15 (0.12, 10.03)
  0.04 (0.00, 1.72)                   0.06 (0.00, 1.85)         0.44 (0.02, 8.98)                1.83 (0.07, 56.23)           0.27 (0.01, 5.44)         **Ligan Hewei therapy + PPIs**   0.30 (0.03, 2.61)
  0.13 (0.01, 3.18)                   0.21 (0.01, 3.07)         1.44 (0.17, 13.42)               6.06 (0.53, 99.03)           0.87 (0.10, 8.10)         3.37 (0.38, 30.87)               **PPIs**
                                                                                                                                                                                         
  Improvement of acid regurgitation                                                                                                                                                      
  **PPIs + GMD**                      **-1.25 (-3.49, 0.92)**   **-0.18 (-1.13, 0.71)**          0.26 (-1.81, 2.18)           -0.31 (-1.93, 1.21)                                        
  1.25 (-0.92, 3.49)                  Jianpi therapy            1.07 (-0.93, 3.10)               1.51 (-0.48, 3.45)           0.93 (-0.56, 2.47)                                         
  0.18 (-0.71, 1.13)                  **-1.07 (-3.10, 0.93)**   Ligan Hewei therapy              0.44 (-1.40, 2.19)           -0.13 (-1.46, 1.13)                                        
  -0.26 (-2.18, 1.81)                 **-1.51 (-3.45, 0.48)**   -0.44 (-2.19, 1.40)              Ligan Hewei therapy + PPIs   -0.58 (-1.84, 0.74)                                        
  0.31 (-1.21, 1.93)                  **-0.93 (-2.47, 0.56)**   0.13 (-1.13, 1.46)               0.58 (-0.74, 1.84)           PPIs                                                       
                                                                                                                                                                                         
  Improvement of heartburn                                                                                                                                                               
  **PPIs + GMD**                      **-0.15 (-0.84, 0.52)**   0.41 (-1.16, 1.92)               **-0.34 (-1.56, 0.85)**                                                                 
  0.15 (-0.52, 0.84)                  **Ligan Hewei therapy**   0.56 (-0.83, 1.91)               **-0.19 (-1.18, 0.78)**                                                                 
  -0.41 (-1.92, 1.16)                 -0.56 (-1.91, 0.83)       **Ligan Hewei therapy + PPIs**   **-0.76 (-1.73, 0.24)**                                                                 
  0.34 (-0.85, 1.56)                  0.19 (-0.78, 1.18)        0.76 (-0.24, 1.73)               PPIs                                                                                    

OR or MD and 95%CrIs below the treatments should be read from row to column while those above should be read from column to row. PPIs, proton pump inhibitors; GMD, gastrointestinal motility drugs.

Bolded data indicated P \< 0.05.

SUCRA Value {#s3_5}
-----------

The SUCRA-based rankings of all treatments are displayed in [**Figure 5**](#f5){ref-type="fig"}. In terms of overall clinical efficacy, Jianpi therapy+PPIs (78.7%) ranked first, followed by Ligan Hewei therapy (71.1%), Ligan Hewei therapy+PPIs (69.2%), Jianpi therapy (67.8%), PPIs (25.4%), GMD (19.6%), and PPIs+GMD (18.3%). However, viewed as a whole, the SUCRA value of efficacy under gastroscope was higher for Ligan Hewei therapy (92.0%) than for any other treatments. As for the improvement of acid regurgitation and heartburn, the highest SUCRA value was found for Ligan Hewei therapy+PPIs (acid regurgitation: 79.4%; heartburn: 90.0%).

![The surface under the cumulative ranking curve (SUCRA) plots of four endpoints. **(A)** Overall clinical efficacy. **(B)** Efficacy under gastroscope.**(C)** Improvement of acid regurgitation. **(D)** Improvement of heartburn.](fphar-11-00884-g005){#f5}

Sensitivity Analysis {#s3_6}
--------------------

A sensitivity analysis was conducted through omitting studies one by one. The result of this analysis showed that there were no significant differences in overall clinical efficacy and efficacy under gastroscope ([**Figure 6**](#f6){ref-type="fig"}).

![Sensitivity analyses of **(A)** overall clinical efficacy and **(B)** efficacy under gastroscope.](fphar-11-00884-g006){#f6}

GRADE Evidence of Quality {#s3_7}
-------------------------

GRADE profiler software, which includes the elements of GRADE criteria such as study design, risk of bias, inconsistency, indirectness, imprecision, and publication bias, was used to rate the quality of evidence and grade strength of recommendations for this network meta-analysis. The results shown in [**Figure 7**](#f7){ref-type="fig"} suggested that the evidence quality of overall clinical efficacy was "Low," which could be related to high risk of bias and indirectness within RCTs.

![GRADE quality grading evaluation.](fphar-11-00884-g007){#f7}

Discussion {#s4}
==========

Network meta-analysis is used to analyze studies with multiple interventions and provide rankings for them ([@B28]). Our findings from the comprehensive network analyses demonstrated the overall synthesis of data for currently available GERD treatments in terms of different THM. Regarding the usage frequency of each herb, a rough conclusion was drawn that herbs with the function of Ligan Hewei and Jianpi were used more frequently among the included herbs. In terms of outcomes, we found that Jianpi therapy+PPIs ranked first in overall clinical efficacy. Ligan Hewei therapy might be a better choice for healing gastroesophageal mucosal lesions according to gastroscope observations. In addition, in the improvement of acid regurgitation and heartburn, Ligan Hewei therapy+PPIs was superior to other interventions. Therefore, Ligan Hewei therapy and Jianpi therapy could be promising complementary and alternative therapies in the management of GERD, which potentially provides TCM practitioners with more suggestions and guidance in clinical decisions, as well as for treatments based on syndrome differentiation.

The pathogenesis of GERD is poorly understood so far. Currently, some acknowledged potential mechanisms are not only involved in hiatal hernia ([@B9]), anti-reflux barrier dysfunction ([@B50]), esophageal inflammation ([@B10]), and transient lower esophageal sphincter relaxation (TLESR) ([@B3]) but have also been associated with psychological factors ([@B2]; [@B47]) and obesity ([@B29]). However, in the modern pharmacological field, complementary and alternative medicine (CAM), especially TCM, could potentially intervene in these mechanisms. A clinical study showed that wu chu yu tang (affiliated to Jianpi therapy) could improve the symptoms of GERD through anti-inflammation, antioxidant activity, acid suppression, reduction in pepsin secretion, and mucosal protection ([@B40]). In the treatment of gastrointestinal (GI) reflux diseases, another study indicated that Wendan decoction (WDD, affiliated with Ligan Hewei therapy) could reduce unhealthy emotions in patients *via* normalizing behaviors and up-regulating orexin-A, orexin receptor 1, and leptin and its receptor in the brain ([@B24]). Additionally, WDD could solve phlegm-related problems and recover GI homeostasis through dual action on acid and bile secretion ([@B51]). Meanwhile, acupuncture regulating qi based on the compatibility of the five meridians (affiliated to Ligan Hewei therapy) could also play an important role in treating GERD with disharmony between liver and stomach syndrome, whose mechanisms were possibly related to its regulation in the neuro-endocrine-immune system, thereby alleviating TLESR, promoting GI motility, suppressing acid secretion, and protecting gastric mucosa ([@B31]). Besides, acupoint drug finger pressing, based on the TCM theory of Jianpi therapy, also showed good therapeutic effects on GERD, which is probably attributable to lower esophageal sphincter pressure promotion and decrease in acid reflux in esophagus, as well as the improvement of coordination of gastroesophageal movement ([@B49]). In sum, CAM, especially TCM, may be multi-target treatments of GERD that are worth studying further *in vitro* and vivo.

Generally speaking, non-randomized trials are susceptible to many biases that affect the weaker forms of evidence. However, in RCTs, certain deficits in their design, conduct, analysis, and reporting may result in bias ([@B38]). In this study, the methodological quality of the included trials was generally moderate, and the quality level of evidence for overall clinical efficacy, according to GRADE evidence classification, was "Low." Analyzing from the above two results, the potential risk of bias in our study was possibly rooted in three aspects. First, there were 13/17 (76.47%) RCTs in which blinding as not implemented, which may lead to the occurrence of performance and detection biases. Next, due to the absence of allocation concealment in all of the included studies, the subjects could easily recognize which treatment they were allocated to, inevitably resulting in selection bias. Last, although 8/17 (47.06%) studies reported detailed withdrawals or dropouts, another 2 (11.76%) failed to provide an adequate explanation for missing data, which may also increase the risk of attrition bias.

In network analysis, consistency is characterized as a single comparison of the relationship between direct and indirect sources of evidence ([@B27]). When consistency is not good in a statistical analysis, it could be short of transitivity. In our study, for primary and secondary outcomes, based on the "node-splitting" method, it showed good convergence and strong stability, thereby further proving high reliability in our results. Nevertheless, clinical heterogeneity, for example, regarding the improvement of symptoms (acid regurgitation and heartburn), which were assessed by the standard excessively subjective judgments by doctors or patients, cannot be ruled out. Also, it should be taken into consideration that overall clinical efficacy and efficacy under gastroscope were described as comprehensive evaluation of the improvement of both many types of GERD symptoms and histopathological changes of gastroesophageal mucosa.

There are several potential limitations to our study. First, the included studies were only in Chinese and Japanese. Evidence with this geographically limited distribution needs more multicenter and large-scale research around the world to support it. Second, discrepancies in traditional herbal medicines (specifically, the interventions mentioned in our study) may exist because of their source and preparation, which could influence the strength of the evidence. Third, missing data could pose a threat to the validity of RCTs because it means that the observed outcomes of an RCT are not representative of all RCTs in the trial. Meanwhile, there was no corresponding evidence to verify its impact on the overall results in our study. Fourth, there was no unified criterion for the classification of interventions. Accordingly, we categorized them by the functions of herbs or prescriptions in the literature. Last, high quality of RCTs plays a key role in the production of optimal sources of evidence.

Therefore, we are looking forward to further standardized research and superior methodology, such as multicenter, large sample sizes, and well-designed (including the implementation of allocation concealment and blinding) RCTs to update and perfect the current body of evidence. Furthermore, strictly following the Consolidated Standards of Reporting Trials (CONSORT) or Standards for Reporting Interventions in Controlled Trials (STRICTA) statement is also essential to improve the reporting quality of future research.

Conclusion {#s5}
==========

Evidence from this network analysis indicates that Ligan Hewei therapy and Jianpi therapy could be the most suitable complementary and alternative interventions for GERD. According to different evaluation outcomes, Jianpi therapy+PPIs could be an optimum treatment in terms of overall clinical efficacy. Ligan Hewei therapy might be suitable for improving gastroesophageal mucosal lesions as seen under a gastroscope. Ligan Hewei therapy+PPIs could be a better choice for patients with acid regurgitation and heartburn. These findings could provide physicians and patients with appropriate treatments based on the specific characteristics of GERD. However, additional high-quality RCTs should be conducted to offer more powerful evidence for future research.
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